

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MARYLAND**

UNITED STATES OF AMERICA

*

*

v.

*

CRIMINAL NO. RWT-10-0694

*

LAUREN STEVENS

*

*

Defendant.

*

GOVERNMENT'S EXHIBIT LIST

EXHIBIT	DATE	DESCRIPTION	ID	OFFER	ADMIT
1	10/9/2002	FDA Initial Inquiry letter to GSK re: Wellbutrin			
2A	10/14/2002	Letter re: Response to FDA			
2B	10/15/2002	Letter re: Teleconference			
2C	10/18/2002	Letter re: Follow-up to teleconference			
2D	10/22/2002	Letter re: Request for information			
2E	10/29/2002	Letter re: Confidentiality of GSK documents			
2F	11/14/2002	Letter re: Response to FDA			
2F-A	11/14/2002	Attachment A to November 14, 2002 Letter from L. Stevens to L. Frank			
2F-B	11/14/2002	Attachment B to November 14, 2002 Letter from L. Stevens to L. Frank			
2G	12/23/2002	Letter re: Response to FDA			
2G-A	12/23/2002	Attachment A to December 23, 2002 Letter from L. Stevens to L. Frank			
2G-B	12/23/2002	Attachment B to December 23, 2002 Letter from L. Stevens to L. Frank			
2G-C	12/23/2002	Attachment C to December 23, 2002 Letter from L. Stevens to L. Frank			
2G-D	12/23/2002	Attachment D to December 23, 2002 Letter from L. Stevens to L. Frank			
2G-E	12/23/2002	Attachment E to December 23, 2002 Letter from L. Stevens to L. Frank			
2G-F	12/23/2002	Attachment F to December 23, 2002 Letter from L. Stevens to L. Frank			
2G-G	12/23/2002	Attachment G to December 23, 2002 Letter from L. Stevens to L. Frank			
2G-H	12/23/2002	Attachment H to December 23, 2002 Letter from L. Stevens to L. Frank			

2G-I	12/23/2002	Attachment I to December 23, 2002 Letter from L. Stevens to L. Frank			
2G-J	12/23/2002	Attachment J to December 23, 2002 Letter from L. Stevens to L. Frank			
2G-K	12/23/2002	Attachment K to December 23, 2002 Letter from L. Stevens to L. Frank			
2G-L	12/23/2002	Attachment L to December 23, 2002 Letter from L. Stevens to L. Frank			
2G-M	12/23/2002	Attachment M to December 23, 2002 Letter from L. Stevens to L. Frank			
2G-N	12/23/2002	Attachment N to December 23, 2002 Letter from L. Stevens to L. Frank			
2G-O	12/23/2002	Attachment O to December 23, 2002 Letter from L. Stevens to L. Frank			
2H	2/28/2003	Letter re: Response to FDA			
2H-A	2/28/2003	Attachment A to February 28, 2003 Letter from L. Stevens to L. Frank			
2H-B	2/28/2003	Attachment B to February 28, 2003 Letter from L. Stevens to L. Frank			
2H-C	2/28/2003	Attachment C to February 28, 2003 Letter from L. Stevens to L. Frank			
2H-D	2/28/2003	Attachment D to February 28, 2003 Letter from L. Stevens to L. Frank			
2H-E	2/28/2003	Attachment E to February 28, 2003 Letter from L. Stevens to L. Frank			
2H-F	2/28/2003	Attachment F to February 28, 2003 Letter from L. Stevens to L. Frank			
2I	3/28/2003	Letter re: Response to FDA			
2I-A	3/28/2003	Attachment A to March 28, 2003 Letter from L. Stevens to L. Frank with Attachments			
2I-B	3/28/2003	Attachment B to March 28, 2003 Letter from L. Stevens to L. Frank with Attachments			
2J	4/28/2003	Letter re: Response to FDA			
2J-A	4/28/2003	Attachment A to April 28, 2003 Letter from L. Stevens to L. Frank with Attachments			
2J-B	4/28/2003	Attachment B to April 28, 2003 Letter from L. Stevens to L. Frank with Attachments			
2J-C	4/28/2003	Attachment C to April 28, 2003 Letter from L. Stevens to L. Frank			

2J-D	4/28/2003	Attachment D to April 28, 2003 Letter from L. Stevens to L. Frank			
2K	5/21/2003	Letter re: Response to FDA			
2K-A	5/21/2003	Attachment A to May 21, 2003 Letter from L. Stevens to L. Frank			
2K-B	5/21/2003	Attachment B to May 21, 2003 Letter from L. Stevens to L. Frank			
2L	11/6/2003	Letter re: Response to FDA			
2L-A	11/6/2003	Attachment A to November 6, 2003 Letter from L. Stevens to R. Williams			
2L-B	11/6/2003	Attachment B to November 6, 2003 Letter from L. Stevens to R. Williams			
2L-C	11/6/2003	Attachment C to November 6, 2003 Letter from L. Stevens to R. Williams			
3	12/12/2002	Letter re: Request for presentation materials used at GSK-Sponsored Programs			
4	1/18/2003	Email from J. Lemieux re: Speaker event and PRIDE databases			
4A	1/20/2003	Spreadsheet of PRIDE Programs (01/06/01-07/28/01): SCS 2001 Rev2-01-18-03.xls			
4B		Spreadsheet of PRIDE Programs - 2002: SCS2002: Rev2-01-18-03 Stat.xls			
4C		Spreadsheet of GSK Speaker Event Database: 2001-2002: SE Database Rev2-01 18 03.xls			
5	1/24/2003	Email re: Doctors' presentations			
6	2/4/2003	Email re: Doctor presentations, K&S review			
7	1/24/2003	Email from J. Lemieux re: Doctors' Presentations			
8	3/18/2003	Email re: Pros/Cons of submitting physician presentations to FDA			
9	6/26/2003	Letter re: Request for presentation materials used at GSK-Sponsored Programs			
10	10/9/2002	Stevens Handwritten Notes - MACMIS notebooks combined			
10A		Stevens Handwritten Notes - MACMIS interviews			
10B		Stevens Handwritten Notes - Non-MACMIS notebooks			
10C		Stevens Handwritten Notes (loose) - Points to Clarify			

10D		Stevens Handwritten Notes - FDA holds co responsible			
10E		Stevens Handwritten Notes (loose) - Pradko			
10F	12/14/2003	Stevens Handwritten Notes (loose) - James Pradko			
10G		Stevens Handwritten Notes (loose) - 1/22/03			
10H		Stevens Handwritten Notes (loose) - Pros/Cons			
10I		Stevens Handwritten Notes (loose) - 7/13/03 Dr. Gordon Clark et al			
10J		Stevens Handwritten Notes (loose) - post-its			
10K		Stevens Handwritten Notes (loose) - Begins 8/29/03			
10L	10/25/2002	Stevens Handwritten Notes (loose) - 10/25/02 Telecon			
10M		Stevens Handwritten Notes 7/24/03-2/27/04 Notebook (black and white copy)			
10N		Stevens Handwritten Notes 10/1/02-7/18/03 Notebook (black and white copy)			
10P		Stevens Handwritten Notes			
11	10/9/2002	Re: NDA 20-358 Wellbutrin SR MACMIS #11170			
12	6/16/2003	Email re: Draft responses to Potential FDA Conference Call questions			
13	11/5/2002	Email re: Provision of presentation materials to FDA			
14	4/25/2003	Letter re: Speakers/presentations; cover letter for list of doctors			
15	6/23/2003	Email re: Letter to Speakers for Wellbutrin SR			
16	10/31/2002	Email attach Draft Project Plan			
17	11/25/2002	Email from L. Stevens re: Update			
17A	4/30/2003	Summary chart of documents sent to King & Spalding			
18	11/26/2002	Email from L. Stevens re: Today's Meeting			
19	1/11/2003	Email from L. Stevens re: List of Documents			
20	10/10/2002	Email re: Letter from DDMAC + FDA Investigation			

21	11/6/2002	Email re: Proceedings of FDA Inquiry; Hull letters to Drs. and Sales reps			
22	10/9/2002	Email from A. Rosen re: FW: Correspondence from DDMAC - Wellbutrin SR			
23	2/5/2003	Email re: Teleconference Agenda			
24	11/5/2002	Email re: Telecon with Lesley Frank			
25	1/30/2003	Memo to King & Spalding re: Teleconference with FDA on January 21, 2003			
26	11/12/2002	Email from L. Stevens re: Qt1 Description of programs for HCPs			
27	1/29/2003	Email from L. Stevens re: SCS 2002 Rev3 - 01 29 03 Stats			
28	2/11/2003	L. Stevens Handwritten notes on revisions to SE database with dates through 2/11/03			
29	5/20/2002	Email from A. Rosen re: Regulatory Requirements for Speakers			
30	5/18/2002	Email from J. Millar re: Review slides and comments			
31	10/16/2003	Email from I. Acosta re: Hudziak Tele Info; Dr. Hudziak Slides			
32	5/20/2002	Email from A. Rosen re: Regulatory Requirements for Speakers			
33	5/14/2002	Email from L. Stevens re: Another Teleconference Question			
34	4/13/2001	Email from R. Rancourt re: Attaching spreadsheet with changes to Wellbutrin SR program plan			
35	5/21/2002	Email from A. Rosen re: FW: Teaching Guidelines			
36	6/5/2002	Email from A. Rosen re: Teaching Guidelines			
37	5/21/2002	Email from L. Stevens re: FW: Teaching Guidelines Dr. Hudziak			
38	2003	J. Hudziak 1099 tax forms			
39	5/29/2002	Email re: J. Ogle re: Transmittal of Hudziak's final slide presentation			
40	4/18/2003	S. Shade Note re: Jamey Millar's meeting with Dr. Hudziak at Advisory Board Meeting			
41	9/5/2003	Email from J. Lemieux re: Dr. Hudziak			
42	3/25/2003	Email from S. Shade re: New Slides for Dr. Hudziak			
43	7/22/2002	Email from J. McNeill re: Discussion re: Hudziak CME schedule			

44	12/16/2002	Email from J. Schell re: FW: Wellbutrin PRIDE Report			
45	5/20/2003	Email from J. Grant re: Transmittal of Hudziak slides			
46	10/4/2002	Fax Cover Sheet from J. Pradko			
47	10/4/2002	Neuroreceptor Basis of Initial Antidepressant Choice presentation			
48	10/4/2002	Handout for presentation			
49	10/6/2002	Fax Cover Sheet and revised slides from J. Pradko			
50	10/7/2002	Email from J. Millar re: Dr. Pradko			
51	10/8/2002	J. Pradko Fax re: Revised slides			
52	11/21/2002	Email from J. Millar re: Pradko 11-15-02 Notes (w/ handwritten notes)			
52A	11/20/2002	E-mail re: FW: Pradko 11/15/02 notes			
52B	11/21/2002	Email from L. Stevens to M. Jensen, M. Brown re: FW: Pradko 11-15-02 Notes			
53	11/22/2002	Letter from J. Pradko re: attach Pradko slides on Neuroreceptor Basis of Initial Antidepressant Choice			
54	11/24/2002	J. Pradko fax cover sheet sending Pradko slides			
55	12/2/2002	Email from L. Stevens re: Request for investigation			
56	12/9/2002	Email from M. Brown re: WBSR.Pradko.letter.12.09.021.doc; letter revisions			
57	12/10/2002	Email from J. Millar re: Letter to Pradko			
58	12/9/2002	Email from S. Shade re: Pradko Letter			
59	12/9/2002	Email from M. Jensen re: Pradko language			
60	12/9/2002	Email from M. Brown re: Pradko and FDA inquiry			
61	12/9/2002	Email from L. Stevens re: Pradko letter			
62	12/10/2002	J. Millar Letter re: Pradko speaker program must be consistent with FDA requirements			
63	12/11/2002	B. Echols Memo to File re: Interview of Anthony Cascarano			
64	12/11/2002	B. Echols Memo to File re: Interview of Marlene May			
65	12/13/2002	L. Stevens Memo to File re: James Pradko			

66	12/9/2002	Email from L. Stevens re: Pradko Letter; Discussion of Pradko presentations			
67	12/13/2002	Email from L. Stevens re: FW: Report on James Pradko			
68	12/17/2002	Email from S. Hull re: Pradko presentation summary			
69A	2/14/2003	Handwritten Notes: 2-13-03 re: James Pradko			
69B	2/7/2003	Letter from L. Stevens to Dr. Pradko regarding 1/24/03 meeting			
70	2/7/2003	Email from J. Millar re: Pradko cassette			
71	2/14/2003	J. Pradko Letter re: Cassette tape lecture			
72	12/15/2002	J. Lemieux Handwritten notes on listing of Pradko events			
73	12/13/2002	Spreadsheet of Dr. Pradko talks			
74A	1/15/2003	Handwritten Notes re: Pradko and CD Rom			
74B	1/15/2003	James Pradko 3/13/2002 Slides			
75	1/19/2003	Choosing an Antidepressant of the Long Haul presentation			
76	2/4/2003	File cover sheet - Pradko			
77	3/18/2003	J. Lemieux cover letter sending Pradko's cassettes to King & Spalding			
78	4/27/2002	J. Pradko Letter re: Use of video			
81	9/19/2002	Memo re: Conference Call Notice on Topic: Use of DVD/CD as a CME Vehicle			
82	10/9/2002	S. Shade Email re: Dr. Pradko			
83	10/9/2002	Jackie Pradko Letter re: Pradko Audiovisual products			
84	10/10/2002	Fax from C. Angelbeck for Conf Call 10/11 (relating to Pradko DVD)			
86	11/17/2002	Fax from B. Prewitt re: forwarding request to purchase Pradko tapes			
87	12/13/2002	Email from A. Rosen re: Memo to the File - SOMA Proposal			
88	12/13/2002	Memo from A. Rosen re: Attachments to the SOMA Memo to the file			
89	1/6/2003	Email from S. Shade re: Pradko DVD			
90	12/30/2002	Document entitled Winning Through Innovation			
91		Pradko audiocassette & transcript (as chalk) Produced as Audio Cassette 46			

92	2/13/2003	Stevens 2002 Performance and Development Plan			
92A	8/21/2003	Letter re: Stevens' Promotion			
92B	2/27/2004	Stevens 2003 Performance and Development Plan			
94		Pradko DVD and transcript (as chalk)			
96	3/23/2000	Memo from R. Padgett re: Pradko Slide Presentation			
97	3/13/2002	Pradko slides: Neuroreceptor Basis of Initial Antidepressant Choice			
98	8/31/2002	GSK Representative Program Evaluation Form			
99		J. Pradko 1099 tax forms			
100	5/12/2003	Email from L. Stevens re: Revised Supplemental Response & Version 2 of Conclusion; Wednesday Teleconference			
101		Lemieux handwritten notes			
101A		Julie Lemieux's telephone log with doctors (includes some notes by Lauren Stevens)			
101B		Julie Lemieux's handwritten notes (loose) - Pradko issue			
101C		Julie Lemieux's handwritten notes - combined			
101D		Lemieux handwritten notes			
101E		Lemieux handwritten notes			
102		Hetzel handwritten notes			
103		Shade handwritten notes			
103A		Sherrie Shade's notes: To Do notebook			
103B		Sherrie Shade's handwritten notes (loose) - from date of press release sent to Lauren Stevens			
103C		Sherrie Shade's handwritten notes (loose) - Fax Hudziak's presentation to Mark			
103D		Sherrie Shade's handwritten notes - Phone Calls notebook			
103E		Sherrie Shade's handwritten notes – on email re: FDA Wellbutrin SR Inquiry (Speaker Programs)			
103F		Sherrie Shade's notes re: speaker programs			
103G		Sherrie Shade's notes re: Q&A 1/11/2003			

103H		Sherrie Shade's notes re: Richard Bennett 1/11/2003			
103I		Sherrie Shade's notes re: Davico and Fujioka			
104		Reeves handwritten notes			
105		Jensen handwritten notes			
106		Brown handwritten notes			
107	2/24/2011	GSK Earnings History - Lauren Stevens			
108	12/20/2002	GSK PRIDE Programs			
109	3/12/2003	Email from J. Lemieux re: FW: Conf. Call			
110	2/26/2003	Email from S. Shade re: Request No. 1 comments from S. Shade			
111	2/25/2003	Email from S. Shade FW: FDA Request No. 1			
112	2/25/2003	Email from L. Stevens re: Anderson Revised Draft; FDA Inquiry about payments to Anderson			
113	10/25/2002	Memo from S. Saini of Telephone conversation re: DDMAC's Wellbutrin inquiry letter			
114	1/18/2003	Email from L. Stevens re: Follow up from sales meeting			
115	2/18/2003	Email from S. Shade re: Response to FDA Inquiry w/ notes			
116	2/15/2003	Email from L. Stevens re: Spoke with Ed Collins			
117	1/22/2003	FDA Information Request: draft response to Request No. 1			
118	2/5/2003	Email from S. Shade re: Teleconference Agenda			
119	3/12/2003	Narrative Response to Requests No. 3, 7, 8 Handout			
120	11/2/2002	Email from M. Schwartz re: Schwartz response to advisory board survey			
121	11/4/2002	Email from M. Schwartz re: SIB Information			
122	11/4/2002	Email from J. Barnes re: Advisory board survey			
123	11/4/2002	Email from G. Dial re: Advisory board survey			
124	11/5/2002	Email from A. Rillo re: Advisory Boards - Wellbutrin SR			
125	11/6/2002	Email from S. Shade re: Arnel response to advisory board survey			

126	11/7/2002	Email from A. Rosen re: Advisory board survey			
127	11/7/2002	Email from J. Barnes re: Advisory board survey			
128	11/7/2002	Email from P. Gaegler re: District 9 advisory board survey			
129	11/7/2002	Email from E. Bishop re: District 5 advisory board survey			
130	4/3/2003	Document and attachment w/ Wolkowitz background info; handwritten notes/edits			
131	11/13/2002	Email from P. Gaegler re: Advisory board survey			
132	12/16/2002	Email M. Jensen re: Teleconference with FDA			
133	12/17/2002	FDA Information Request: draft response to Request No. 1			
134	1/22/2003	Email from S. Shade Draft response to FDA Information Request No. 1			
135	1/19/2003	FDA Information Request: draft response to Request No. 1			
136	1/29/2003	Email from L. Stevens re: Request No. 1 comments			
137	2/12/2003	FDA Information Request: draft response to request No. 1			
138	2/14/2003	Email from L. Stevens re: FDA Information Request: draft response to request No. 1			
139	2/13/2003	Email re: Request No. 1 comments from S. Shade and L. Stevens			
140	2/19/2003	Email re: Request No. 1 comments from M. Brown			
141	10/4/2002	GSK (US) Policy on GlaxoSmithKline-Sponsored Speaker Programs			
142	6/4/2001	Email re: New GSK Policies on Commercial Practices			
143	4/4/2003	Document containing GSK Speaker Event policies			
144	9/19/2003	Email from L. Stevens re: Gadde response to agreement			
145	5/23/2002	Email re: Recent changes to GSK's commercial practices policies			
146	11/13/2001	Memo re: P.R.I.D.E. 2002 Program Roll-out			
147	11/15/2002	Document w/names/bios of Wellbutrin employees who train speakers			

148	6/30/2003	Memoranda: Interview Summaries; Document Index from GSK			
149	9/18/2003	Email from L. Stevens re: Wellbutrin SR Sustained-Release Tablets-- Response to GSK Request for Presentation Materials Used at GSK- Sponsored Programs			
150	6/14/2003	Memo from M. Brown to L. Stevens re: Talking points for Teleconference w/ FDA			
151	10/30/2003	Email from S. Shade re: Draft response			
152	1/24/2003	Email from M. Jensen re: Letters relating to Dr. presentations			
153	11/15/2002	Email from L. Stevens re: Q&A for physicians and sales reps re FDA inquiry			
154	5/1/2003	Email from L. Stevens re: requesting RVPS in region for list of doctors to receive regulatory letter			
155	4/25/2003	List of Dr.s' names, those involved in inquiry			
156	2/25/2003	Email from M. Brown re: Wellbutrin talks			
157	3/30/2003	Email from M. Brown re: Response to slide request of Wolkowitz by Mark Brown			
158	10/10/2002	Document w/handout of slides for talk on 6/27/02			
159	2/22/2003	Email from L. Stevens re: FDA Investigation of Wellbutrin, Dr. Owen Wolkowitz			
160	4/24/2003	Fax re: Discussion on Depression with Dr. Wolkowitz			
161	4/17/2003	Email from M. Brown re: Wolkowitz questions about FDA inquiry			
163	12/2/2002	Email from L. Stevens re: Draft response to Owen Wolkowitz			
164	10/10/2002	S. Shade Project Plan with Stevens Notes			
165	1/15/2003	GSK PRIDE Programs spreadsheet			
166	1/10/2003	Email from R. Moscato re: FW: PRIDE 2003 Questions			
167	1/30/2003	Email from L. Stevens re: Speaker Event database for Wellbutrin SR			
167A	1/22/2003	GSK Speaker Event Database - Wellbutrin SR - 2001 -2002: SE Database Rev3 01 22 03.xls			

168	3/13/2003	Email from J. Lemieux re: Speaker Database Comments, Requests No. 3, 7, 8			
169	3/17/2003	Email from L. Stevens re: SE Database rev 3-17-03 #5			
170	4/17/2003	Email from S. Shade re: GSK response to FDA inquiry			
171	1/16/2003	Email from L. Esposito re: FW: Wellbutrin PRIDE 2001			
172	1/3/2003	Spreadsheet of PRIDE Programs with Compensation (01/06/01-07/28/01)			
174	10/10/2002	Handwritten Chart			
175	3/28/2003	GSK PRIDE Programs 2001 (submitted to FDA)			
176	3/26/2003	FDA Information Request: draft, with email attached from M. Jensen			
177	5/5/2003	Email from M. Brown re: draft response to request 13, 14 and conclusion			
178	3/18/2003	Draft of March letter regarding the PRIDE and SE Databases with revisions			
179	9/18/2003	Email from L. Stevens re: Middleman, Satloff response to agreement			
180	1/18/2003	Spreadsheet w/ comments on presentations mention weight			
181	5/12/2003	Email from L. Stevens with comments on draft conclusion			
182	1/9/2003	K. Fujioka Letter re: Lectures for GSK			
183	2/8/2003	Envelope from Alexander to Stevens with Stevens note attached			
184	1/18/2003	Revised Spreadsheet: Presentations w/ other off-label issues			
185	1/11/2003	Notes from Sherrie Shade about Bennet's slides			
186	1/13/2003	File cover sheet for Neil Berliner			
187	1/13/2003	File cover sheet for Kishore Gadde			
188	1/14/2003	File cover sheet for Don Chesler			
189	1/14/2003	File cover sheet for David Dunner			
190	1/1/2003	File cover sheet for Daniel Deutschman			
191	9/29/2003	Responses regarding June 26, 2003 Letter to Doctors spreadsheet			
192	9/24/2003	Email from L. Hedgpeth re: Removal of Dr. Kishore Gadde from SE			
193	2/13/2003	Email from S. Shade re: FW: Speaker Presentations			

194	8/5/2003	Email from J. Lemieux re: List of Physicians who have not responded to 7-26 letter			
195	1/24/2003	Handout re: Review of Doctor Responses with handwritten comments			
196	1/15/2003	Note re: Deutschman handouts used in 2001 presentations			
197	1/15/2003	Note from rep states slides were used during lunch time talks			
198	1/15/2003	Note from rep states slides were used during lunch time talks			
199	12/11/2002	Note re: Number of doctors who spoke at speaker events and through PRIDE			
200	12/16/2002	Spreadsheet with list of doctors added onto the original 500			
201	4/29/2003	List of doctors to get regulatory/contract letter			
202	10/22/2003	Email from L. Stevens to sales reps re: off-label speaker programs			
203	10/31/2003	Email from S. Shade re: Draft Letter			
204	10/20/2003	Draft response to 6/9/03 letter re: Davico			
205	10/26/2003	Draft of early Nov letter to FDA			
206	11/5/2003	Email from L. Stevens re: draft response to 10/9/02 letter			
207	11/5/2003	Email M. Brown re: draft response to 10/9/02 letter			
208	11/6/2003	Draft response to 10/9/02 letter ("Margaret's")			
209	11/6/2003	Draft response to 10/9/02 letter with handwritten edits			
210	11/6/2003	Draft response to 10/9/02 letter			
211	6/16/2003	Email from S. Hull re: Formal grievance of Davico			
212	11/5/2002	Email from S. Saini re: Pre-disclosure notification request by GSK			
214	10/17/2003	Forwarded email from L. Stevens re: James Sahoye interview memo attached			
215	11/22/2002	Email from J. Lemieux re: List of Documents			
216	2/12/2003	Email from L. Stevens re: New database for speaker programs that used off-label title			
217	10/15/2002	Email from D. Clines re: Cover Letter for Slide Request			

218	2/19/2003	Email from N. Reeves re: Revised Anderson narrative; Anderson presentations			
219	12/19/2002	Email from L. Stevens re: Draft Nov. letter to FDA			
220	12/20/2002	Email from S. Shade re: Draft Cover Letter, training slide for RMS			
221	12/23/2002	Email from L. Stevens re: Final Letter to FDA			
222	1/14/2003	Spreadsheet of Response from Doctors			
223	1/22/2003	Outline of Questions from FDA teleconference			
223A	1/25/2003	Email re: Outline of FDA teleconference from previous week			
224	1/24/2003	Email from L. Stevens re: Spreadsheet for WLBCTRS75 exchange project			
225	11/11/2002	Email attachment from J. Lemieux re: RMS PRIDE Speaker update slides			
226	1/1/2011	King & Spalding Invoices			
227	1/1/2011	King & Spalding Billing Summary			
228	12/17/2003	Email from M. Brown re: GSK Wellbutrin SR: memo to L. Stevens summarizing investigation			
229	6/14/2002	Letter to FDA's Russell Katz re off-label promotion			
230	9/22/2010	Letter from Medical Education Collaborative.			
231	9/22/2010	Stevens Training Records re: 016 Compliance Guidance			
232	5/21/2003	Spreadsheet of Names, Company Address; Rate Quality of Program and Speaker for MEC Audioconference - Stevens Training			
233	10/4/2002	Materials from University of North Carolina School of Law, Dan K. Moore Ethics Program.			
234	5/1/2002	Lauren Stevens training materials PhRMA 5/1/02 - 5/3/02			
235	6/29/2010	North Carolina State Bar Records re: L. Stevens			
236	11/4/2003	Draft response to 10/9/02 letter with handwritten edits			
237	2/23/2003	Email from L. Stevens re: Issues regarding payments to Drs.			

238	10/3/2003	Powerpoint presentation re: Treatment Options for Depression by J. Amato in Primary Care with email attached			
239	7/29/2002	Email from J. Millar re: Dr. Hudziak and new State law			
240	11/18/2003	Memo to Clayton File from J. Lemieux			
241	10/15/2003	Email from L. Stevens re: Amato off-label presentation			
242	8/15/2002	Email from R. Moscato re: CME Express program Hudziak			
243	12/18/2002	Handouts used by Modell during GW/GSK sponsored talks			
244	6/22/2000	Effect of Bupropion-SR on Orgasmic Dysfunction in Nondepressed Subjects: A Pilot Study			
245	12/16/2002	Email from S. Shade re: FW: Speaker Presentations			
246	2/6/2003	Voice Mail from Jack Modell regarding his follow-up on presentation materials			
247	11/4/2003	Email from L. Stevens re: Anita Clayton Slides			
248	6/28/2001	Wellbutrin SR presentations			
249	7/2/2001	Announcement of Fujioka presentations			
250	7/17/2001	Email from J. Persinger re: Summary Forms for 2000 and 2001 SIBS			
251	11/30/2001	GSK Special Issues Board Executive Summary			
252	9/3/2002	Email from J. McNeill re: CME Express for Depression			
253	8/30/2003	Email from B. Judd re: Memo of General Pharma Speaker Policy			
254	11/4/2003	Email from L. Stevens re: draft response to 10/9/02 letter			
255	10/31/2003	Email attachment from S. Shade listing of non-PRIDE Fujioka programs			
256	10/1/2003	Email from M. Brown re: confirmation to interview James Sahoye			
257	9/24/2003	Email from L. Stevens re: Gadde removal from speaker database			
258	6/26/2003	Letter from L. Stevens to K. Fujioka re: Request for Presentation Materials Used at GSK-Sponsored Programs			
259	6/9/2003	Letter from A. Davico to E. Hu re: Off-label promotion of Wellbutrin SR by Glaxo SmithKline			

260	8/7/2003	Letter from L. Stevens to M. Zetin re: Discusses response to GSK's request re: use of GSK materials in presentations			
261	1/28/2003	Fax from C. Gessner to K. Fujioka re: Enclosing for signature speaker event confirmation, amendment to GSK agreement with GSK speaker events, member promotional programs			
262	1/15/2001	K. Fujioka Slides re: Effects of Bupropion SR on Body Weight			
263	6/15/2002	K. Fujioka presentation - Antidepressants and Weight Gain			
264	6/15/2002	K. Fujioka presentation - Depression and Obesity			
265	3/7/2003	Memo from R. Rancourt re: coaching and counseling			
266	1/27/2003	Email from S. Shade re: memo on call with FDA			
267	2/12/2003	Email from L. Stevens re: Response to FDA Inquiry			
268	9/30/2003	Document re: FDA Letter of Inquiry + GSK Internal Investigation; Notes on sales reps and Drs.			
269	2/24/2002	Thorpe HR and compliance file			
270	2/2/2001	Letter from T. Abrams re: DDMAC awareness of presentations by Dr. McMillen on behalf of Pharmacia			
271	9/17/2001	Warning Letter from T. Abrams re: promotional activities of Merck & Co for Vioxx			
272	2/1/2002	Warning Letter from T. Abrams re: promotional activities of Pharmacia Corp. for Celebrex			
273	10/25/2002	Email from J. Millar re: CAT obesity study with Anderson			
274	10/29/2002	Email from M. Brown re: Final Review of letter			
275	10/29/2002	Email from M. Brown re: NYT Article on Neurontin and efforts to promote off-label uses			
276	10/30/2002	Email from M. Brown re: FOIA request to FDA			
277	11/6/2002	Email from J. Millar re: Slide showing uses for Wellbutrin SR by indication			
278	11/20/2002	Email from L. Stevens re: Chart examining uses of WBSR by indication			

279	11/14/2002	Email from L. Frank re: Document re RMS presentation to Trainees			
280	12/3/2002	Email from M. Jensen re: Summary of Documents and Information Requested from Interviews			
281	12/2/2002	Email from L. Stevens re: FW: Interview Summaries			
282	12/3/2002	Wellbutrin SR Investigation, Next Steps document			
283	12/11/2002	Email from L. Stevens w/ attached PhRMA Code on Interactions w/ Healthcare Professionals			
284	12/15/2002	L. Stevens Notes re: speaker issues			
285	12/17/2002	Email from L. Stevens re: Description of presentation by Dr. James Pradko			
286	12/18/2002	Fax from L. Stevens re: NDA 20-358 Wellbutrin SR Sustained-Release Tablets MACMIS #11170			
287	1/14/2003	File cover sheet - Dr. Ken Fujioka			
288	2/25/2003	Email from M. Brown re: FDA Inquiry concerning payments to Anderson			
289	3/12/2003	Email from J. Hetzel re: Today's Teleconference w/ K&S			
290	4/22/2003	Email from L. Stevens re: Dr. Wolkowitz background doc w/ edits			
291	5/1/2003	Email from L. Stevens re: conference call re: strategy			
292	5/8/2003	Email from N. Reeves re: Conclusion version #2 revisions			
293	5/29/2003	Email from L. Stevens re: Imitrex and Wellbutrin; Lesley Frank			
294	6/5/2003	Email from L. Stevens re: Teleconference to discuss submissions in Wellbutrin matter			
295	6/15/2003	Email from S. Shade re: Gov't Statement of Interest in the Franklin case			
296	10/1/2003	Email from L. Stevens re: GSK qui tam plaintiff question; other discussion regarding plaintiff			
297	10/3/2003	Email from T. Thelen re: Management Change			
298	10/17/2003	Email from M. Brown re: Presentation to DDMAC			
299	2/22/2002	Email from C. Singer re: PRIDE program and Greg Thorpe			

300	7/15/2002	CNN.com article "study shows antidepressant may fight obesity"			
309	5/1/2002	Email from I. Acosta re: Rescheduling Fujioka's PRIDE programs			
317	12/17/2002	Email from S. Janning re: Wellbutrin Slide Review Follow Up			
318	12/12/2002	Letter from L. Stevens re: Wellbutrin SR (bupropion HCI) Sustained-Release Tablets Request for Presentation Materials Used at GSK-Sponsored Programs			
327	3/9/1993	Memo from R. Ingram re: Speakers Bureau			
328	3/12/1993	Email from M. Werner re: AMA Guidelines to Sales Reps			
329	6/12/1998	Email from A. Witty re: Speaker Training Inquiry			
330	6/12/1998	Email from R. Wolgemuth re: Speaker Training Inquiry			
334	10/28/2002	Project Plan with handwritte notes			
335	10/31/2002	Draft Project Plan			
336	7/18/2001	Letter from L. Morgan re: Obesity Point of View			
339	11/11/2002	Email from L. Stevens including final version of letters to sales reps and doctors requesting presentation material			
340	10/1/2001	Email from D. Childs re: Objective re: Speaker's Training for Wellbutrin SR			
341	10/3/2001	Press Release re: TAP Pharmaceutical products charged with health care crimes			
342	11/9/2001	GSK invite to "Weighing Your Choices for Antidepressant Selection" by Fujioka			
343	9/15/2002	Powerpoint re Lamictal investigation			
344	9/24/2002	GSK (US) Policy on GSK-Sponsored Speaker Programs			
345	10/10/2002	Email from C. Angelbeck re: Follow-Up Conf Call			
346	11/18/2002	Document w/ organizational chart of employees; brief handwritten note contained			
347	12/23/2002	Email from L. Stevens to S. Hull re: update on submitting FDA documents			
348	1/15/2003	File cover sheet - Modell			

349	2/12/2003	Letter from M. Brown to J. Anderson requesting review of draft of letter to FDA			
350	4/15/2003	Fax from N. Reeves re: Changes in information provided by Dr. Wolkowitz			
351	6/4/2003	Email from N. Reeves re: attachment Wellbutrin SR June draft of talking points			
352	6/12/2003	Email from L. Stevens re: incorporating Stan's changes in draft			
353	6/15/2003	US Statement of Interest in United States ex rel Franklin v. Parke-Davis			
354	6/20/2003	Press Release - AstraZeneca pleads guilty to healthcare crime			
355	10/30/2002	Email from L. Stevens attaching Merck pdf; Pharmacia doctor.pdf; Pharmacia.pdf			
357	6/12/2010	Letter Agreement with John Hetzel			
359	3/2/2009	Letter Agreement with Julie Lemieux			
360	2/25/2009	Agreement with Lemieux			
361	12/17/2003	Email from N. Reeves re: GSK remedial actions			
365	10/24/2007	Order re: James Millar			
366	5/13/2008	Agreement between USAO and Marlene May			
368	11/7/2003	Email from B. Judd re: Professional programs compliance review third quarter 2003			
369	12/31/2003	Memo re: Speaker events - Top Fee Recipients			
370	1/2003	Memo re: Compliance Review Highlights - First Quarter 2003			
371	2/10/2003	Email re: December 2002 Professional Programs Compliance Report – select pages			
372	4/16/2001	Memo re: Top 10 Speakers by Product			
373	1/5/2004	Email from G. Bean re: Transmittal of Top Ten Speakers by Product			
374	6/2002	Wellbutrin SR Prescribing Information - Product Label June 2002 (small print)			
375	6/2002	Wellbutrin SR Product Information - Product Label June 2002 report (large print)			

376	10/10/2002	Email from T. Thelen re: FDA investigation into activities relating to Wellbutrin			
377	12/16/2002	Email from L. Stevens re: Teleconference with Dr. Clayton			
378	11/12/2002	Email from S. Shade re: Tentative Interview Schedule			
379	12/4/2002	Email from L. Stevens attaching Wall Street Journal article			
380	10/31/2001	S. Hull Slideshow on Wellbutrin SR			
400	1/3/2003	Spreadsheet: SCS2001 Rev1 – 1-08-03.xls			
401	2001	Spreadsheet of GSK Pride Programs - 2001: Rev. 1A of SCS 2002			
402	1/2002	Spreadsheet of 2002 PRIDE Programs: SCS2002 – Orig Stats.xls			
403	1/29/2003	Spreadsheet of GSK PRIDE Programs - 2002: SCS2002 Rev. 3 – 1/29/03 stats.xls			
404	3/18/2003	Memo re: Simplified Chart Addressing FDA Statements			
406	11/4/2002	Email from G. Romanowski re: Advisory Boards - Wellbutrin SR			
407	10/27/2003	Email from L. Stevens re: FW: Questions on PRIDE Utilization			
408	1/20/2003	Email from L. Hedgpeth re: SE Database compen 12 17 02.xls			
409	10/2/2002	Email from T. Schaffer re: James Pradko, MD Depression Slide deck			
410	1/16/2003	Email from L. Stevens re: FW: re: Postponing call w/ FDA			
411	10/7/2002	Email from T. Schaffer re: Fw: Pradko xls			
412	3/28/2003	Email from L. Stevens re: FW: FW: SIB Information			
412A	1/11/2000	Attachment to FW: FW: SIB Information: Tentative Schedule			
413		North Carolina State Bar Rules – Selected Rules			
415	11/26/2002	Email from L. Esposito re: WEL Speaker Information			
416	10/29/2002	Email from L. Stevens re: Final Review of letter			
417	12/2/2002	Email from L. Stevens re: Draft Response to Owen Wolkowitz			

418	10/26/2002	SCS Reconcil Report of PRIDE Programs As of 10/26/01 (By Date) document and spreadsheet			
419	4/13/2003	Email from L. Stevens re: 41692_2_doc			
420	1/29/2003	Email from L. Stevens re: SCS-2001 w attendees orig 01 29 03.xls; SCS 2002 Rev3 - 01 29 03 Stats.xls			
421	8/8/2003	Email from M. Rodriguez re: Corporate Integrity Agreement with Government (attached)			
422	4/9/2003	Settlement Agreement and Release (USA and GSK)			
423	4/16/2003	Press Release - Bayer Corporation and GlaxoSmithKline to Pay \$344 Million to Resolve Allegations of Health Care Fraud Against State Programs			
424	9/2/2003	Email from L. Stevens to T. Thelen, C. Grant, S. Shade, M. Brown, D. Snyder re: Aldo Davico & Wellbutrin Investigation			
425	9/10/2003	Email from L. Stevens to R. Arjun, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: Also Davico			
426	9/10/2003	Stevens Handwritten Notebook re: Topic Outline for GSK Wellbutrin SR Interviews			
427	12/17/2002	Email from S. Shade re: FW: Interview Outline			
428	11/6/2002	Email from S. Shade re: FW: Advisory Boards - Wellbutrin SR			
429	5/9/2003	MDM Teleconference Call General Questions with annotations			
430	5/9/2003	MDM Teleconference Call General Questions			
431	11/7/2002	Email from S. Shade re: FW: Wellbutrin SR Advisory Board Information for Region B8			
432		Master File James Pradko (1 redwell)			
433		Master File Doctor Slides (2 boxes)			
434		Lauren Stevens File (1 redwell)			
435	11/4/2002	Email from M. Schwartz re: SIB Information			
436		Envelope of SIBS documents			